View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmasimple 過去の業績過去 基準チェック /06Pharmasimpleの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Specialty Retail 業界の成長14.47%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Jun 2021最近の業績更新Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).すべての更新を表示Recent updatesBoard Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.お知らせ • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.分析記事 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).分析記事 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.分析記事 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.収支内訳Pharmasimple の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史ENXTPA:ALPHS 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 2132-51031 Mar 2139-31031 Dec 2046-20030 Sep 2045-20030 Jun 2044-10031 Mar 2036-20031 Dec 1928-30030 Sep 1926-30030 Jun 1923-20031 Mar 1920-20031 Dec 1817-20030 Sep 1818-20030 Jun 1818-20031 Mar 1819-20031 Dec 1719-10030 Sep 1717-10030 Jun 1715-10031 Mar 1713-10031 Dec 1611-10031 Dec 15700031 Dec 14500031 Dec 134000質の高い収益: ALPHSが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: ALPHSの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: ALPHSの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: ALPHSの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: ALPHSの過去 1 年間の収益成長がSpecialty Retail業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: ALPHSは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YRetail 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/09 01:14終値2024/02/09 00:00収益2021/06/30年間収益2020/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmasimple SA これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Florent Thy-TineTPICAP Midcap
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
お知らせ • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.
分析記事 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...
Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.
Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.
Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
分析記事 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.
分析記事 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.